Express Scripts aims to ensure that patients directly benefit from its negotiations with drug manufacturers. The new approach will protect patients from paying inflated list prices for medications, instead providing them with the lower prices negotiated by the PBM, according to a Jan. 29 news release from the company.

Fresh off underperforming Wall Street’s expectations in the fourth quarter, Cigna said it would work to lower costs for its customers amid widespread discontent with the healthcare system.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and Blue Shield Plans, was found guilty of engaging in horizontal price-fixing in collaboration with Express Scripts,

Health insurer Cigna's unit Evernorth Health said on Wednesday it will make changes to help lower out-of-pocket cost of prescription drugs for patients at its pharmacy stores. The changes will protect patients from paying a high list price for their medication by giving them access to lower prices negotiated by Cigna's pharmacy benefit manager,

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

The National Community Pharmacists Association has joined a class action lawsuit against GoodRx, as well as CVS Caremark, Express Scripts, MedImpact Healthcare Systems and Navitus Health Solutions, th

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.